ArriVent Financial Statements From 2010 to 2025

AVBP Stock   19.50  1.06  5.16%   
ArriVent BioPharma, financial statements provide useful quarterly and yearly information to potential ArriVent BioPharma, Common investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on ArriVent BioPharma, financial statements helps investors assess ArriVent BioPharma,'s valuation, profitability, and current liquidity needs. Key fundamental drivers impacting ArriVent BioPharma,'s valuation are summarized below:
Market Capitalization
699.4 M
Earnings Share
(2.56)
There are currently eighty-five fundamental signals for ArriVent BioPharma, Common that can be evaluated and compared over time across rivals. Investors and active traders are advised to validate ArriVent BioPharma,'s prevailing fundamental performance against the performance between 2010 and 2025 to make sure the trends are evolving in the right direction.
Check ArriVent BioPharma, financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among ArriVent BioPharma,'s main balance sheet or income statement drivers, such as Depreciation And Amortization of 26.7 M, Selling General Administrative of 9.5 M or Other Operating Expenses of 44.1 M, as well as many indicators such as Price To Sales Ratio of 0.0, Ptb Ratio of 8.91 or Days Sales Outstanding of 0.0. ArriVent financial statements analysis is a perfect complement when working with ArriVent BioPharma, Valuation or Volatility modules.
  
Check out the analysis of ArriVent BioPharma, Correlation against competitors.

ArriVent BioPharma, Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Total Assets182.6 M316.2 M99.6 M
Slightly volatile
Other Current Liabilities16.1 M15.3 M4.6 M
Slightly volatile
Total Current Liabilities10.7 M19.9 M5.5 M
Slightly volatile
Total Stockholder Equity171.8 M296.3 M94.1 M
Slightly volatile
Accounts Payable3.2 M4.3 M1.4 M
Slightly volatile
Cash117 M85.4 M62.5 M
Slightly volatile
Non Current Assets Total57.9 M55.2 M10.3 M
Slightly volatile
Non Currrent Assets Other137.7 K144.9 K267.3 K
Pretty Stable
Other Assets0.80.90.9813
Slightly volatile
Cash And Short Term Investments156.7 M251.7 M84.4 M
Slightly volatile
Net Receivables553 K575 K352.4 K
Slightly volatile
Common Stock Shares Outstanding26.5 M30.3 M32.8 M
Slightly volatile
Liabilities And Stockholders Equity182.6 M316.2 M99.6 M
Slightly volatile
Other Current Assets4.6 M8.8 M1.9 M
Slightly volatile
Other Stockholder Equity599.2 M570.6 M106.7 M
Slightly volatile
Total Liabilities10.8 M19.9 M5.5 M
Slightly volatile
Total Current Assets168.4 M261 M92 M
Slightly volatile
Net Working Capital157.7 M241.2 M86.5 M
Slightly volatile
Common Stock2.9 K2.7 K3.7 K
Slightly volatile
Short and Long Term Debt Total231.7 K202.4 K162.2 K
Slightly volatile
Short Term Debt157.7 K186.3 K136.4 K
Slightly volatile
Short Term Investments115.7 M130.1 M141.9 M
Slightly volatile
Long Term Investments38.1 M42.9 M46.8 M
Slightly volatile

ArriVent BioPharma, Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization26.7 M42.4 M19.2 M
Slightly volatile
Selling General Administrative9.5 M17.6 M5.7 M
Slightly volatile
Other Operating Expenses44.1 M85.8 M25.7 M
Slightly volatile
Research Development49.7 M90.9 M24.1 M
Slightly volatile
Total Operating Expenses59 M108.5 M29.3 M
Slightly volatile

ArriVent BioPharma, Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
Stock Based Compensation3.9 M3.7 M801.4 K
Slightly volatile
Other Cashflows From Financing Activities539.5 K567.9 K95.9 M
Slightly volatile
Total Cash From Financing Activities134.5 M214.6 M108.5 M
Slightly volatile
End Period Cash Flow117 M85.4 M62.5 M
Slightly volatile
Begin Period Cash Flow128.7 M172.9 M66.4 M
Slightly volatile
Issuance Of Capital Stock146.9 M213.8 M164.3 M
Pretty Stable

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
PTB Ratio8.914.8613.5521
Slightly volatile
Book Value Per Share2.984.261.997
Slightly volatile
PB Ratio8.914.8613.5521
Slightly volatile
Cash Per Share2.864.241.8775
Slightly volatile
Income Quality0.620.87230.4004
Slightly volatile
Net Debt To EBITDA1.911.811.1765
Slightly volatile
Current Ratio19.913.139922.0099
Slightly volatile
Tangible Book Value Per Share2.984.261.997
Slightly volatile
Shareholders Equity Per Share2.984.261.997
Slightly volatile
Debt To Equity0.00137.0E-49.0E-4
Slightly volatile
Graham Net Net2.683.921.7726
Slightly volatile
Interest Debt Per Share0.00560.00890.0049
Slightly volatile
Debt To Assets0.00126.0E-49.0E-4
Slightly volatile
Price Book Value Ratio8.914.8613.5521
Slightly volatile
Ebt Per Ebit1.021.074.6977
Slightly volatile
Effective Tax Rate0.180.20.2203
Slightly volatile
Company Equity Multiplier0.851.06711.0358
Slightly volatile
Total Debt To Capitalization0.00137.0E-49.0E-4
Slightly volatile
Debt Equity Ratio0.00137.0E-49.0E-4
Slightly volatile
Quick Ratio19.9113.139922.0118
Slightly volatile
Cash Ratio4.094.300917.934
Slightly volatile
Price To Book Ratio8.914.8613.5521
Slightly volatile
Debt Ratio0.00126.0E-49.0E-4
Slightly volatile
Price Fair Value8.914.8613.5521
Slightly volatile

ArriVent Fundamental Market Drivers

Cash And Short Term Investments218.9 M

About ArriVent BioPharma, Financial Statements

ArriVent BioPharma, shareholders use historical fundamental indicators, such as revenue or net income, to determine how well the company is positioned to perform in the future. Although ArriVent BioPharma, investors may analyze each financial statement separately, they are all interrelated. The changes in ArriVent BioPharma,'s assets and liabilities, for example, are also reflected in the revenues and expenses on on ArriVent BioPharma,'s income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Last ReportedProjected for Next Year
Current Deferred Revenue(0.90)(0.94)

Pair Trading with ArriVent BioPharma,

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if ArriVent BioPharma, position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in ArriVent BioPharma, will appreciate offsetting losses from the drop in the long position's value.

Moving together with ArriVent Stock

  0.77A Agilent TechnologiesPairCorr
  0.69ME 23Andme HoldingPairCorr

Moving against ArriVent Stock

  0.66DVAX Dynavax TechnologiesPairCorr
  0.37VALN Valneva SE ADRPairCorr
The ability to find closely correlated positions to ArriVent BioPharma, could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace ArriVent BioPharma, when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back ArriVent BioPharma, - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling ArriVent BioPharma, Common to buy it.
The correlation of ArriVent BioPharma, is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as ArriVent BioPharma, moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if ArriVent BioPharma, moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for ArriVent BioPharma, can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Additional Tools for ArriVent Stock Analysis

When running ArriVent BioPharma,'s price analysis, check to measure ArriVent BioPharma,'s market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ArriVent BioPharma, is operating at the current time. Most of ArriVent BioPharma,'s value examination focuses on studying past and present price action to predict the probability of ArriVent BioPharma,'s future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ArriVent BioPharma,'s price. Additionally, you may evaluate how the addition of ArriVent BioPharma, to your portfolios can decrease your overall portfolio volatility.